Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 24
Summary
- Conditions
- Metastatic Melanoma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Description Patients who fulfill eligibility criteria will be entered into the trial to receive tremelimumab and MEDI3617. After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. The investigator...
Description Patients who fulfill eligibility criteria will be entered into the trial to receive tremelimumab and MEDI3617. After the screening procedures confirm participation in the research study: The participant will be given a study drug-dosing calendar for each treatment cycle. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have melanoma, not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated. Tremelimumab MEDI3617
Tracking Information
- NCT #
- NCT02141542
- Collaborators
- MedImmune LLC
- Investigators
- Principal Investigator: Patrick Ott, MD Dana-Farber Cancer Institute
Get Well Soon